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Neurobiology of Disease
Systemic Inflammation Alters the Kinetics of
Cerebrovascular Tight Junction Disruption after
Experimental Stroke in Mice
BarryW. McColl, Nancy J. Rothwell, and Stuart M. Allan
Faculty of Life Sciences, University of Manchester, Manchester M13 9PT, United Kingdom
Systemic inflammatory events, such as infection, increase the risk of stroke and are associated with worse outcome, but themediators of
this clinically important effect are unknown. Our aim here was to elucidate mechanisms contributing to the detrimental effects of
systemic inflammation onmild ischemic brain injury inmice. Systemic inflammation was induced inmice by peripheral interleukin-1
(IL-1) challenge and focal cerebral ischemia by transient middle cerebral artery occlusion (MCAo). Systemic inflammation caused an
alteration in the kinetics of blood–brain barrier (BBB) disruption through conversion of a transient to a sustained disruption of the tight
junction protein, claudin-5, and also markedly exacerbated disruption to the cerebrovascular basal lamina protein, collagen-IV. These
alterations were associated with a systemic inflammation-induced increase in neurovascular gelatinolytic activity that was mediated by
a fivefold increase in neutrophil-derived matrix metalloproteinase-9 (MMP-9) in the brains of IL-1-challenged mice after MCAo.
Specific inhibition of MMP-9 abrogated the effects of systemic inflammation on the sustained but not the acute disruption of claudin-5,
which was associated with phosphorylation of cerebrovascular myosin light chain. MMP-9 inhibition also attenuated the deleterious
impact of systemic inflammation on brain damage, edema, neurological deficit, and incidence of hemorrhagic transformation. These
data indicate that a transformation from transient to sustained BBB disruption caused by enhanced neutrophil-derived neurovascular
MMP-9 activity is a critical mechanism underlying the exacerbation of ischemic brain injury by systemic inflammation. These mecha-
nisms may contribute to the poor clinical outcome in stroke patients presenting with antecedent infection.
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Introduction
Stroke is the second most common cause of mortality and the
leading cause of adult neurological disability worldwide (Meairs
et al., 2006). There is growing evidence that the susceptibility to
stroke and subsequent prognosis are influenced by systemic in-
flammatory processes (McColl et al., 2007b; Emsley and Hop-
kins, 2008). Acute infection,mainly of bacterial origin and affect-
ing the respiratory or urinary tracts, increases the risk of stroke,
particularly in the first few days after infection (Smeeth et al.,
2004; Clayton et al., 2008), and poorer outcome in stroke patients
presenting with antecedent infection has been reported (Palasik
et al., 2005; Zeller et al., 2005).Other established risk factors, such
as atherosclerosis, obesity, type 2 diabetes, periodontal disease,
and rheumatoid arthritis are also linked to an elevated systemic
inflammatory status (Mu¨ller-Ladner et al., 2005; Wellen and
Hotamisligil, 2005;Hansson and Libby, 2006;Moutsopoulos and
Madianos, 2006). Systemic inflammation has now been shown to
markedly exacerbate brain damage in experimental models of
cerebral ischemia (McColl et al., 2007a; Spencer et al., 2007).
The mechanisms underlying the impact of systemic inflam-
mation on the outcome to ischemic brain injury are poorly un-
derstood, although we recently demonstrated a critical role for
neutrophils in an experimental paradigm (McColl et al., 2007a).
Neutrophils contain a number of proteolytic enzymes stored in
intracellular granules, notably the serine proteases, cathepsin G
and elastase, and the gelatinase, matrix metalloproteinase-9
(MMP-9) (Borregaard and Cowland, 1997). MMP-9, in particu-
lar, is strongly implicated as a pathological mediator during the
acute phase after stroke. Putative mechanisms include the prote-
olysis of neurovascular substrates such as tight junction proteins
essential for blood–brain barrier (BBB) integrity and compo-
nents of the extracellular matrix integral to cerebrovascular and
neuronal viability (Zhao et al., 2007). In contrast to the classic
biphasic response, which involves acute and delayed periods of
BBB opening (Belayev et al., 1996; Rosenberg et al., 1998), we
previously showed that a peripheral inflammatory challenge re-
sults in an unremitting increase in BBB permeability after exper-
imental stroke (McColl et al., 2007a). Although the molecular
basis for this is unknown, it is conceivable that alterations in
neurovascular proteolytic activitymay be important inmediating
effects of systemic inflammation on stroke damage.
To test this hypothesis and to identify the molecular effectors
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of the detrimental effects of systemic inflammation on ischemic
brain injury, we have used a previously validated model of sys-
temic inflammation induced by peripheral administration of the
cytokine, interleukin-1 (IL-1) (McColl et al., 2007a). We have
shown previously that the effects of IL-1 challenge on stroke in
mice are indistinguishable from those induced by the bacterial
endotoxin, lipopolysaccharide (McColl et al., 2007a), and that
effects of the latter are inhibited by the IL-1 receptor antagonist.
Moreover, localized peripheral and systemic actions of IL-1
contribute to conditions that predispose to stroke, such as infec-
tion (Dinarello, 1992), atherosclerosis (Kirii et al., 2003), and
type 2 diabetes (Larsen et al., 2007). We show that systemic in-
flammatory challenge causes sustained BBB disruption and
poorer outcome after MCAo via an MMP-9-mediated pathway.
Materials andMethods
Mice. All experiments were performed on 10–12-week-old (25–30 g)
C57BL/6J mice (Harlan) under appropriate UK Home Office personal
and project licenses and adhered to regulations as specified in the Ani-
mals (Scientific Procedures) Act (1986).
Focal cerebral ischemia. Focal ischemia was induced by transient (30
min) middle cerebral artery occlusion (MCAo) as described previously
(McColl et al., 2007a). Briefly, core body temperature was regulated at
37 0.5°C.Under halothane anesthesia (30%O2, 70%N2O), a 6-0 nylon
monofilament (Dermalon) with 2 mm tip (180 m diameter) coated in
thermo-melting glue (Jet Melt) was introduced into the external carotid
artery and advanced along the internal carotid artery (ICA) until occlud-
ing the origin of the MCA. After 30 min, the filament was withdrawn to
establish reperfusion. Sham-operated mice underwent the same proce-
dure except the filament was advanced along the ICA and then immedi-
ately withdrawn.
Drug administration. All treatments were administered in a blinded
manner by intraperitoneal injection in a volume of 4 ml/kg. Systemic
inflammation was induced by injection of recombinant IL-1 (10 IU;
National Institute for Biological Standards and Controls, UK) diluted in
vehicle (0.5% endotoxin-free bovine serum albumin in sterile PBS) 30
min before the onset of MCAo. To block MMP-9, we used the specific
inhibitor, SB-3CT. SB-3CT is a highly selective mechanism-based gelati-
nase inhibitor with particular specificity for MMP-9 and has previously
been shown to specifically inhibit MMP-9-driven pathways in disease
models in vivo (Gu et al., 2005; Bonfil et al., 2006). We verified this
selectivity in vitro; SB-3CT inhibitedMMP-9- but notMMP-2-mediated
gelatinase activity in medium from IL-1-treated glial cells. SB-3CT (20
mg/kg diluted in 0.1%DMSO in sterile saline; Biomol International) was
administered 30 min before the induction of MCAo and 4 h after the
onset of reperfusion.
Neutrophil depletion. To deplete neutrophils, mice received three in-
jections of rabbit anti-PMN IgG (2 mg/kg; Accurate Scientific) or rabbit
IgG as control at the same dose diluted in sterile saline. One injectionwas
given per day for 3 d before MCAo.
Assessment of neurological deficit. Neurological status was assessed
blinded to drug treatment and according to a neurological grading score
of increasing severity of deficit (Bederson et al., 1986): 0, no observable
deficit; 1, torso flexion to right; 2, spontaneous circling to right; 3, lean-
ing/falling to right; 4, no spontaneous movement.
Tissue processing. For measurement of ischemic damage and brain
edema and for in situ zymography, mice were perfused transcardially
with 0.9% saline then brains removed and snap-frozen in isopentane on
dry ice. For immunohistochemistry,micewere perfusedwith 0.9% saline
followed by 4% paraformaldehyde. Brains were removed, postfixed,
cryoprotected (15% sucrose), and frozen in isopentane on dry ice. For all
experiments, sections (20 m) were cut on a cryostat (Leica Microsys-
tems). For immunoblotting and gel zymography, mice were perfused
with 0.9% saline, and striatal and cortical brain samples were rapidly
removed and frozen in dry ice. Frozen samples were homogenized on ice
in buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM CaCl2, 0.02%
NaN, 1% Triton X-100) and then centrifuged (14,000 g for 30 min at
4°C). Protein concentration was determined in supernatants by BCA
protein assay (Pierce) and all samples equilibrated to a concentration of
2 mg/ml total protein.
Assessment of ischemic brain damage and edema. Ischemic damage and
edema were measured blinded to drug treatment as described previously
(McColl et al., 2007a). Adjacent sections were stained with hematoxylin
and eosin to detect hemorrhagic transformation (HT).
Immunohistochemistry. Antibodies used were as follows: goat anti-
MMP-9 (1:500; R&D Systems), rabbit anti-neutrophil SJC (1:100; kindly
provided by Drs. Daniel Anthony and Sandra Campbell, University of
Oxford, Oxford, UK), mouse anti-neuronal-specific nuclear protein
(neuN) to label neurons (1:50; Millipore), rabbit anti-GFAP to label
astrocytes (1:500; Dako), rabbit anti-iba1 to label microglia (1:500;
Wako), rabbit anti-claudin-5 (1:200; Zymed Laboratories), rabbit
anticollagen-IV (1:500; Abcam), rabbit anti-phosho-myosin light chain
(MLC) (1:50; Cell Signaling Technology). Endogenous peroxidase activ-
ity was blocked (this step omitted for double-labeling immunofluores-
cence) with 0.3% H2O2 in methanol and nonspecific binding sites
blocked with 10% normal serum (Vector Laboratories). Sections were
incubated in primary antibody (diluted in 5% normal serum in PBS)
overnight at 4°C. For peroxidase-based staining, sections were then in-
cubatedwith appropriate biotinylated secondary antibody (1:200 in PBS;
Vector Laboratories) before incubation in Vectastain ABC solution
(Vector Laboratories) and development of staining by diaminobenzidine
reaction (Vector Laboratories). Sectionswere lightly counterstainedwith
cresyl violet. For double-labeling immunofluorescence, after primary an-
tibody incubation, sections were incubated with Alexa fluorochrome-
conjugated secondary antibodies (1:1000 in PBS; Invitrogen) and
mounted with ProLong Gold containing 4,6-diamidino-2-
phenylindole dihydrochloride (DAPI) counterstain (Invitrogen).
Quantification of MMP-9 immunostaining. Cerebral MMP-9 immu-
noreactivity was quantified blinded to treatment. The number of MMP-
9-immunopositive cells was counted in three fields of the cortex (so-
matosensory, insular, piriform) or striatum (dorsal, lateral, ventral) at
two coronal levels (0.2 mm and0.5 mm relative to bregma). Themean
was calculated from the six fields in the cortex or striatumand adjusted to
express as mean number of cells/mm2.
Immunoblotting. Antibodies used were as follows: rabbit anti-
claudin-5 (1:500; Zymed Laboratories), goat anti-occludin (1:1000;
Santa Cruz Biotechnology), rabbit anti-collagen-IV (1:1000; Abcam),
rabbit anti-laminin (1:100; Sigma-Aldrich). Homogenized samples
(containing 50 g protein) were separated by SDS-PAGE and proteins
transferred to polyvinylidene difluoride membrane. Membranes were
blocked [10% nonfat milk in 0.01% PBS-Tween20 (PBS-T)] and incu-
bated in primary antibody (diluted in 1% bovine serum albumin in
PBS-T) overnight at 4°C. Membranes were then incubated with horse-
radish peroxidase-conjugated secondary antibody (in 5% milk in PBS-
T). Blots were developed using an Enhanced Chemiluminescent Detec-
tion Kit (GE Healthcare) and protein bands visualized on x-ray film
(Biomax MR1; Kodak). Semiquantitative densitometry was performed
on digitized images using Northern Eclipse software.
Gel zymography. Protein samples were purified for gelatinases as de-
scribed previously (Zhang and Gottschall, 1997). Briefly, samples (con-
taining 1.5 mg protein) were incubated with gelatin-Sepharose beads
(GEHealthcare) for 1 h at 4°C with gentle agitation. After centrifugation
(14,000  g for 2 min at 4°C), the gelatin-Sepharose pellet containing
bound gelatinases was washed (in homogenization buffer without deter-
gent) and the purified gelatinases then separated from beads by incuba-
tion with elution buffer (10% DMSO in wash buffer) for 30 min at 4°C
with constant agitation followed by centrifugation. Purified samples (25
l) were separated on SDS-polyacrylamide gels impregnated with 1.5
mg/ml gelatin under nonreducing, nondenaturing conditions. SDS was
removed to renature enzymes by incubating gels in wash buffer (50 mM
Tris-HCl, pH 7.6, 5 mM CaCl2, 1 M ZnCl2, 2.5% Triton X-100). Gels
were then incubated in reaction buffer (wash buffer without detergent)
for 72 h at 37°C to stimulate gelatinolysis. Gels were stained with Coo-
massie Brilliant Blue R-250 (0.1%) diluted in 40% methanol and 10%
acetic acid for 1 h and destained in a solution containing 10% methanol
and 1% acetic acid until clear gelatinolytic bands appeared. Gels were
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dried and semiquantitative densitometry per-
formed on digitized images using Northern
Eclipse software.
In situ zymography. Snap-frozen unfixed sec-
tions were incubated with reaction buffer (50
mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM
CaCl2, 1 M ZnCl2, 0.02% NaN) containing 20
g/ml FITC-conjugated DQ gelatin (Invitro-
gen) overnight at 37°C. Gelatinases cleave the
gelatin resulting in uncaging of the conjugated
FITC and in increase in fluorescence corre-
sponding to the extent of proteolytic activity.
Sections were washed and mounted with Pro-
Long Gold (Invitrogen). Some sections were
coincubated with the broad-spectrum MMP
inhibitor, GM-6001 (Calbiochem). For colocal-
ization of gelatinolytic activity, immunofluo-
rescence was performed as described above im-
mediately after zymography.
Microscopy.Brightfield images were collected
on a Zeiss Axioskop upright microscope and
captured using Zeiss Axiovision software.
Widefield fluorescence images were collected
on an Olympus BX51 upright microscope and
captured using MetaVue software (Molecular
Devices). Confocal images were collected using
a Nikon Eclipse 90i upright confocal micro-
scope. Fluorescent images were processed using
ImageJ software.
Statistical analysis. Parametric data were an-
alyzed using Student’s t test for single compar-
isons or one-way ANOVA followed by Stu-
dent’s t test with Bonferroni correction for
multiple comparisons. Correlation coefficients
were computed using Pearson correlation.
Nonparametric data were analyzed using
Kruskal–Wallis test followed by Dunn’s test for
multiple comparisons. Categorical data (neu-
rological deficit scores) were analyzed using
generalized Fisher’s exact test with Bonferroni
correction. Statistical significance was assumed
at p 0.05.
Results
Systemic inflammation alters the
kinetics of BBB
tight-junction disruption
We showed previously that a systemic in-
flammatory challenge exacerbates BBB
permeability and brain edema afterMCAo
(McColl et al., 2007a). In view of the fun-
damental role of tight junctions in regulat-
ing BBB permeability, we examined the ef-
fects of systemic inflammation on the tight
junction proteins, claudin-5 (Fig. 1A–C)
Figure 1. Systemic inflammation causes sustained claudin-5 disruption after MCAo. Systemic inflammation was induced by
intraperitoneal IL-1 injection, and the effects on the BBB tight junction proteins, claudin-5 and occludin, were assessed in
cortical tissue ipsilateral toMCAoby immunoblot and immunofluorescence at indicated times afterMCAo.A,MCAo induceda50%
reduction in claudin-5 levels in both vehicle (veh)- and IL-1-treated mice compared with sham-operated mice after 4 h reper-
fusion. This disruption to claudin-5 resolved in vehicle-treated mice by 8 h after MCAo and was maintained at 24 h in which
claudin-5 levels were similar to sham-operated mice. There was a sustained disruption to claudin-5 in IL-1-treated mice 8 and
24 h after MCAo resulting in a 70% reduction compared with sham-operated mice at 24 h. The sustained loss of claudin-5 in
IL-1-challengedmice resulted in a significant reduction comparedwith vehicle-treatedmice8and24hafterMCAo.B, Claudin-5
immunofluorescence (green channel) with DAPI counterstain (blue channel) demonstrated dense networks of cerebrovascular
immunoreactivity in sham-operatedmice.Marked reductions in immunoreactivitywere evident 4hafterMCAO in vehicle-treated
4
mice and 4, 8, and 24 h afterMCAo in IL-1-challengedmice,
consistent with the immunoblot data. C, Confocal immuno-
fluorescence revealed the disruption by systemic inflamma-
tion to the highly organized arrangement of claudin-5 in the
interendothelial tight junctions of cortical blood vessels in the
ipsilateral hemisphere 24 h after MCAo.D, There were no sig-
nificant effects of systemic inflammation orMCAoonoccludin
levels. All immunofluorescence images are from the cortex
ipsilateral toMCAo. *p0.05 versus vehicle; Student’s t test.
Scale bars: B, 100m; C, 10m.
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and occludin (Fig. 1D), themajor interen-
dothelial junctional proteins limiting
paracellular permeability at the BBB.
MCAo induced a 50% reduction in
claudin-5 protein compared with sham-
operatedmice after 4 h reperfusion in both
vehicle and IL-1-challenged mice (Fig.
1A). After 8 h reperfusion, a similar
MCAo-induced reduction in claudin-5 to
that at 4 h was observed in IL-1-
challengedmice. In contrast, claudin-5 ex-
pression in vehicle-treated mice was com-
parable with that in sham-operated mice.
Claudin-5 expression was significantly re-
duced in IL-1-challenged mice com-
pared with vehicle-treated mice at this
time point ( p 0.05). After 24 h reperfu-
sion there was further disruption to
claudin-5 in IL-1-challenged mice with
levels reduced to 30% of sham-operated
mice. Claudin-5 was also significantly re-
duced at 24 h compared with vehicle-
treated mice ( p  0.05) which showed
comparable levels to sham-operated
animals.
Disruption of claudin-5 was further ex-
amined by immunofluorescence (Fig. 1B).
Immunoreactivity was restricted to the ce-
rebral vasculature, and in sham-operated
mice dense networks of penetrating arte-
rioles andmicrovessels were immunoreac-
tive (Fig. 1B). In parallel with the immu-
noblot data, MCAo induced a marked loss
of immunoreactivity after 4 h reperfusion
in vehicle and IL-1-challenged mice. A
sustained loss of immunoreactivitywas ev-
ident in IL-1-challengedmice as reperfu-
sion progressed. In contrast, the disrup-
tion was transient in vehicle-treated mice
with the pattern of immunostaining simi-
lar to sham-operated mice 8 and 24 h after
MCAo (Fig. 1B). Confocal microscopy
highlighted the density and precise inter-
endothelial location of claudin-5 in indi-
vidual vessels. A highly regular and orga-
nized arrangement of claudin-5
immunoreactivity was evident in sham-
operated and vehicle-treated mice 24 h af-
ter MCAo, whereas marked disorganiza-
tion and fragmentation was seen in IL-1-
challenged mice (Fig. 1C).
In contrast to claudin-5,MCAo did not
cause disruption of occludin in vehicle- or
IL-1-challenged mice at any time point
(Fig. 1D).
Systemic inflammation exacerbates
cerebrovascular basal lamina disruption
The integrity of the BBB is dependent on
adequate structural and biochemical sup-
port from the basement membrane that
closely apposes the abluminal surface of
the endothelial monolayer (del Zoppo and
Figure 2. Systemic inflammation aggravates cerebrovascular collagen-IV disruption after MCAo. Systemic inflammation was
induced by intraperitoneal IL-1 injection and the effects on the cerebrovascular basement lamina proteins, collagen-IV, and
laminin, were assessed in cortical tissue ipsilateral to MCAo by immunoblot and immunofluorescence at indicated times after
MCAo. A, Collagen-IV levels in vehicle (veh)-treated mice were similar in sham-operated mice and after MCAo at all time points
examined. IL-1 challenge caused a progressive decline in collagen-IV as reperfusion progressed and resulted in an 80% reduc-
tion comparedwith sham levels 24 h afterMCAo. Therewas a significant reduction in collagen-IV levels in IL-1-challengedmice
compared with vehicle-treated mice 8 and 24 h after MCAo, and a putative cleavage collagen-IV cleavage product (circled) was
evident in IL-1-challenged mice at these time points. B, Collagen-IV immunofluorescence (green channel) with DAPI counter-
stain (blue channel) demonstrated extensive and dense networks of cerebrovascular immunoreactivity in sham-operated mice
and a similar patternwas evident in vehicle-treatedmice afterMCAo. IL-1 challenge induced amarked reduction in collagen-IV
immunoreactivity 4, 8, and 24 h after MCAo. C, Systemic inflammation or MCAo did not significantly affect laminin levels. All
immunofluorescence images are from the cortex ipsilateral toMCAo. *p 0.05 versus vehicle; Student’s t test. Scale bar, 50m.
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Milner, 2006). Therefore, we next determined whether systemic
inflammation affects the disruption of the key basal lamina com-
ponents, collagen-IV and laminin, after MCAo (Fig. 2). There
was no effect of MCAo on collagen-IV levels in vehicle-treated
mice at any time point assessed. After 4 h reperfusion, IL-1
challenge induced a modest reduction in collagen-IV levels rela-
tive to sham-operated mice, but there was no significant differ-
ence compared with vehicle-treated mice (Fig. 2A). There was,
however, a progressive reduction in collagen-IV levels as reper-
fusion continued to 8 and 24 h after MCAo in IL-1-challenged
mice, and at these time points there was a
significant reduction compared with
vehicle-treated mice ( p  0.05). In addi-
tion to the progressive loss in 160 kDa
collagen-IV, we also observed the appear-
ance of a smaller band of80 kDa thatwas
consistently present in all samples from
IL-1-challenged mice but only rarely (2
of 6) in vehicle-treated mice 8 and 24 h
after MCAo. This band was not present in
sham-operated mice or 4 h after MCAo
suggesting that it may represent a
collagen-IV cleavage product and that sys-
temic inflammation aggravates proteolytic
degradation of the full-length species.
The pattern of collagen-IV immuno-
staining on brain sections was consistent
with the immunoblotting results. Immu-
noreactivity was associated exclusively
with the cerebral vasculature, and dense
networks of collagen-IV-labeled vessels
were observed in sham-operated mice
(Fig. 2B). Amodest reduction in immuno-
reactivity was observed in vehicle-treated
mice in response to MCAo, but the dura-
tion of reperfusion did not demonstrably
affect the extent of immunoreactivity. In
contrast, as reperfusion progressed in IL-
1-challenged mice, we observed a pro-
gressive reduction in collagen-IV immu-
noreactivity resulting in amarked loss 24 h
after MCAo (Fig. 2B).
The major laminin immunoreactive
band was observed at 200 kDa, likely cor-
responding to the 4 isoform enriched in
the vascular basement membrane. There
were no significant changes in laminin lev-
els in response to MCAo or IL-1 chal-
lenge (Fig. 2C). Immunohistochemistry
on brain sections confirmed the preserva-
tion of vessel-associated laminin; however,
we did observe scattered loss of neuronal-
associated laminin 24 h after MCAo (data
not shown) consistent with a previous
study (Gu et al., 2005).
Systemic inflammation exacerbates
neurovascular gelatinolytic activity
Several mechanisms may contribute to
BBB disruption after stroke. Foremost
among these is the proteolytic disruption
of BBB substrates, including tight junction
and basal lamina proteins, associated with
neurovascular MMP activity. We next determined whether sys-
temic inflammation affects gelatinase (MMP-9 and MMP-2)-
derived proteolytic activity in the brain afterMCAo using gel and
in situ zymography (Fig. 3). MMP-9 activity was undetectable at
any time point in sham-operated mice. A band corresponding to
murine pro-MMP-9 (105 kDa) was evident in vehicle and IL-1-
challenged mice 8 and 24 h after MCAo. There was negligible
induction of MMP-9 activity 4 h after MCAo and no difference
between vehicle and IL-1-challengedmice (Fig. 3A). After 8 and
24 h reperfusion, IL-1-challenge resulted in a significant in-
Figure 3. Systemic inflammation exacerbates neurovascular gelatinolytic activity. A, B, Systemic inflammation was induced
by intraperitoneal IL-1 injection and the extent of gelatinolytic activity determined by gel zymography in purified cortical brain
samples (A) and by in situ zymography on brain sections at indicated times after MCAo (B). A, Gelatinolytic activity was minimal
4hafterMCAo, and therewasnodifferencebetweenvehicle (veh)- and IL-1-treatedmice. Clear gelatinolytic bands correspond-
ing to pro-MMP-9 (105 kDa) and active MMP-9 (97 kDa) were evident 8 and 24 h after MCAo in vehicle- and IL-1-treated mice
but not after sham occlusion. The extent of gelatinolytic activity (105 kDa) was significantly greater in IL-1-treated mice 8 and
24 h after MCAo. There was no detectable gelatinolytic activity corresponding toMMP-2 (72 kDa). B, In situ zymography demon-
strated that increased gelatinolytic activity in IL-1-challenged mice was primarily localized to the cerebral vasculature and
neurons 8 and 24 h after MCAo. In situ gelatinolytic activity wasminimal in sham-operatedmice and attenuated by coincubation
with the MMP-9 inhibitor, SB-3CT. C, Immunofluorescence was combined with in situ zymography to confirm the localization of
gelatinolytic activity. D, Gelatinolytic activity colocalized with the vascular basement membrane protein, laminin, and the neu-
ronal marker neuN. **p 0.01 versus vehicle; Student’s t test. Scale bars: B, 100m; C, 15m; D, 25m.
McColl et al. • Systemic Inflammation and Ischemic BBB Disruption J. Neurosci., September 17, 2008 • 28(38):9451–9462 • 9455
crease in MMP-9 activity ( p 0.01) (Fig.
3A). The activated formofmurineMMP-9
(97 kDa) was also detectable at these time
points. In contrast to MMP-9 activity, no
gelatinolysis at the 72 kDa level (corre-
sponding to MMP-2) was detected after
sham surgery or MCAo suggesting that
MMP-2 was not induced by peripheral in-
flammatory challenge or ischemia. This is
consistent with neutrophils representing
the major source of MMP-9 in the post-
ischemic brain because these cells do not
produce MMP-2 (Van den Steen et al.,
2002). Furthermore, we did not detect in-
duction of MMP-3 by immunohisto-
chemistry (data not shown), another
MMP that has been implicated in BBB
disruption.
To further assess the spatiotemporal
induction of MMP activity, we used in situ
zymography. Gelatinolytic activity was not
detectable after 4 h reperfusion in vehicle
or IL-1-challenged mice (data not
shown). An induction of activity was ob-
served 8 and 24 h after MCAo and was
markedly greater in IL-1-treated mice
compared with vehicle-treated (Fig. 3B).
After 8 h reperfusion, IL-1 treatment re-
sulted in intense and extensive proteolytic
activity throughout cortical tissue, which
was primarily localized to the microvascu-
lature and to a lesser extent surrounding
neuronal cell bodies. Peri-neuronal activ-
ity increased further 24 h afterMCAo. Ad-
dition of the specific MMP-9 inhibitor,
SB-3CT, to the incubation medium abol-
ished gelatinolytic activity indicating that
MMP-9 was the gelatinase responsible for
proteolysis (Fig. 3B). Colocalization with
laminin (Fig. 3C) and neuN (Fig. 3D) con-
firmed the vascular and neuronal localiza-
tion of in situ gelatinolytic activity. These
observations are consistent with the gel zy-
mography datawhich show specific induc-
tion of MMP-9 and together suggest that
systemic inflammation exacerbates neutrophil MMP-9-driven
proteolysis of neurovascular substrates.
Infiltrating neutrophils are the major source of increased
MMP-9 caused by systemic inflammation
Cells resident in the brain and infiltrating immune cells can ex-
press MMP-9 in the postischemic brain suggesting that systemic
inflammation could enhanceMMP-9 activity by stimulating res-
ident brain cells via immune-brain signaling or via increased traf-
ficking ofMMP-9-laden cells into the brain.We next investigated
the cellular source(s) responsible by examining the spatiotempo-
ral profile of cerebral MMP-9 immunoreactivity after MCAo
(Fig. 4). MMP-9 immunoreactivity was evident in the striatum
and cortex of the hemisphere ipsilateral to MCAo but not in the
contralateral hemisphere or in sham-operatedmice. MMP-9 was
localized to cells within blood vessels, including penetrating ves-
sels (Fig. 4A) andmicrovessels (Fig. 4B), and to cells throughout
the parenchyma (Fig. 4C). MMP-9 immunoreactivity was more
abundant andmore extensively distributed in IL-1-treatedmice
when compared with vehicle-treated, particularly after 8 or 24 h
reperfusion (Fig. 4D). Quantification of cellular MMP-9 in the
striatum showed a general decline in the number of MMP-9
cells as reperfusion progressed (Fig. 4E). The number of
MMP-9 cells in the striatum was significantly greater in IL-1-
challenged mice 8 h after MCAo ( p  0.05). In contrast, the
number of MMP-9 cells in the cortex increased as reperfusion
progressed and IL-1 challenge resulted in a significant increase
in MMP-9 immunoreactivity at all time points after MCAo (4
and 8 h, p 0.05; 24 h, p 0.01).
The distribution and localization ofMMP-9 immunostaining
was strikingly similar to the pattern of neutrophil infiltration we
reported previously (McColl et al., 2007a). To determinewhether
neutrophils were the major source of MMP-9 in this paradigm,
we performed double-labeling immunofluorescence (Fig. 5). We
observed strong colocalization between MMP-9 and the
neutrophil-specific marker, SJC, but not with neuronal (neuN),
Figure 4. Systemic inflammation increases cerebral MMP-9 immunoreactivity after MCAo. Systemic inflammation was in-
duced by intraperitoneal IL-1 injection and MMP-9 immunostaining assessed at indicated times after MCAo. A–C, MMP-9
immunostainingwas evident in cells adherent to cortical penetrating vessels (A) andmicrovessels (B) and in cells throughout the
parenchyma (C) in the hemisphere ipsilateral toMCAo. Therewasminimal immunoreactivity in the contralateral hemisphere and
in sham-operated mice. D, Representative brain sections illustrate the marked increase in MMP-9-immunoreactive cells in the
cortexof IL-1-treatedmice8and24hafterMCAo.E, Quantificationof cellularMMP-9 immunoreactivity. Systemic inflammation
significantly increased the number of MMP-9 cells in the cortex 4, 8, and 24 h after MCAo and in the striatum 8 h after MCAo.
*p 0.05, **p 0.01 versus vehicle (veh); Student’s t test. Scale bars: (in C) A–C, 25m; D, 100m.
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microglial/macrophage (Iba1), or astrocytic (GFAP) markers
(Fig. 5A). We also observed strong colocalization between
MMP-9 and the vascular basement membrane protein, laminin
(Fig. 5A). The vascular (and cellular) MMP-9 immunoreactivity
was lost in neutropenic mice but not in mice treated with an
isotype control (Fig. 5B), suggesting that the vascular MMP-9
was neutrophil-derived and confirming neutrophils as the key
source of MMP-9 in the ischemic brain in our model. This was
further substantiated by a strong correlation between the
number of MMP-9 cells and neutrophils (r 2  0.91; p 
0.001) (Fig. 5C). These data suggest that systemic inflamma-
tion exacerbates cerebrovascular and parenchymal MMP-9
levels and activity by increasing the trafficking of peripheral
immune cells, particularly neutrophils, into the brain.
Inhibition of MMP-9 abrogates the delayed and sustained
disruption to BBB substrates caused by systemic
inflammation
The temporal profile of exacerbated MMP-9 activity was con-
sistent with the sustained disruption to claudin-5 after MCAo
caused by systemic inflammation. We
next determined directly whether
MMP-9 was responsible for the systemic
inflammation-induced alteration in the
kinetics of BBB disruption after MCAo.
MMP-9 inhibition did not significantly
affect the reduction in claudin-5 levels in
vehicle- or IL-1-treated mice 4 h after
MCAo (Fig. 6A). The claudin-5 disrup-
tion resolved by 8 h after MCAo in
vehicle-treated mice regardless of
whether MMP-9 was inhibited or not.
This resolution in vehicle-treated mice
was maintained at 24 h after MCAo and
again was independent of MMP-9 inhi-
bition. In contrast, the sustained reduc-
tion in claudin-5 levels in IL-1-
challenged mice 8 and 24 h after MCAo
was significantly ( p  0.05) attenuated
by MMP-9 inhibition (Fig. 6A).
MMP-9 inhibition had no effect on
collagen-IV levels in vehicle-treated mice,
and levels were similar to sham-operated
mice at all time points examined (Fig. 6B).
There was a trend toward reduced
collagen-IV levels 4 h after MCAo in IL-
1-challenged mice, and MMP-9 inhibi-
tion restored levels to those in sham-
operated mice. MMP-9 inhibition
significantly attenuated the reduction in
collagen-IV 8 and 24 h after MCAo in IL-
1-challenged mice ( p  0.05). At the
later time points, MMP-9 inhibition pre-
vented the appearance of the 80 kDa im-
munoreactive band, a potential
collagen-IV cleavage product.
Together, these data suggest that sys-
temic inflammation can drive a sus-
tained MMP-9-dependent disruption of
the BBB that supersedes and compounds
a previous MMP-9-independent disrup-
tion that can resolve in the absence of
systemic inflammation.
Phosphorylation of cerebrovascular myosin light chain
occurs independently of systemic inflammation 4 h after
MCAo
The data above suggest an MMP-9-independent disruption to
claudin-5, 4 h after MCAo. The resolution of claudin-5 disrup-
tion in vehicle-treated mice by 8 h also suggested a protease-
independentmechanism, because cleavage of claudin-5would be
expected to induce a prolonged effect. Therefore, we next as-
sessed whether MCAo triggered brain endothelial MLC phos-
phorylation, a critical step in brain endothelial cytoskeletal reor-
ganization and tight junction disruption in vitro (Afonso et al.,
2007). Using an antibody that specifically detects phosphoryla-
tion of serine19 of MLC, we observed an increase in phosphory-
lated MLC 4 h after MCAo in vehicle- and IL-1-treated mice
compared with sham-operated mice (supplemental figure, avail-
able at www.jneurosci.org as supplemental material). Increased
MLC phosphorylation was observed in microvessels of diameter
10 m deep in the cerebral cortex. These vessels do not have a
surrounding smooth muscle layer indicating that the observed
Figure 5. Infiltrating neutrophils are the primary source of MMP-9 in the ischemic brain. The cellular localization of MMP-9
immunoreactivity in the ischemic brain was examined by double-labeling immunofluorescence. A, There was strong and exten-
sive colocalization between MMP-9 and the specific neutrophil marker, SJC, but not with neuronal (neuN), astrocytic (GFAP), or
microglial (Iba1)markers. Therewas also strong colocalizationofMMP-9with the vascular basementmembraneprotein, laminin.
B, Depletion of neutrophils using an anti-PMNantibody abolished the cellular and vascularMMP-9 immunoreactivity in the brain,
but there was no effect with an isotype control antibody. C, There was a strong correlation between the number of MMP cells
and the number of neutrophils in the cortex of vehicle- and IL-1-treated mice. R 2 0.91; p 0.01, Pearson correlation. All
double-labeling immunofluorescence images are from the cortex ipsilateral toMCAoof IL-1-treatedmice 24h afterMCAo. Scale
bars: A, 25m; B, 100m.
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response was attributable to phosphoryla-
tion of endothelial MLC. Phosphorylated
MLC was also apparent in large cortical
surface arteries which do contain smooth
muscle (supplemental figure, available at
www.jneurosci.org as supplemental mate-
rial), but there was no induction com-
pared with sham-operated mice, perhaps
reflecting the constitutive function of
these vessels in regulating cortical
perfusion.
Systemic inflammation exacerbates
ischemic brain injury via anMMP-9
dependent mechanism
In view of the important role of BBB dys-
function in ischemic brain damage, the
transformation from transient to sus-
tained tight-junction disruption caused
by systemic inflammation and mediated
by MMP-9 is likely to have a marked ef-
fect on outcome after stroke. Therefore,
we next determined whether the sys-
temic inflammation-induced MMP-9-
dependent sustained disruption to BBB
substrates is an important mechanism
underlying the exacerbation of brain
damage after mild focal ischemia we
demonstrated previously (McColl et al.,
2007b) (Fig. 7). Peripheral IL-1 chal-
lenge significantly exacerbated (2-fold)
the extent of ischemic brain damage
( p  0.05) (Fig. 7A), brain edema ( p 
0.05) (Fig. 7B), and the severity of neu-
rological deficit ( p 0.05) (Fig. 7C) and
also caused HT of infarcts in two of six
mice. Inhibition of MMP-9 significantly
attenuated the effects of peripheral
IL-1 on damage ( p  0.05), edema
( p  0.05), and neurological deficit
( p 0.05), and prevented HT (Fig. 7D).
The abrogation of brain injury was pri-
marily the result of an attenuation of
damage in cortical tissue (Fig. 7E), and
there was no effect of MMP-9 inhibition
in vehicle-treated mice. These results are
consistent with the predominance of in-
flammatory processes in cortical tissue
and the mainly anoxic/excitotoxic modes of cell death operat-
ing in the striatal core. Inhibition of MMP-9 also attenuated
the effect of peripheral inflammatory challenge on cortical
neutrophil accumulation (Fig. 7F ) and gelatinolytic activity
(Fig. 7F ).
Discussion
The present data provide an explanation for the deleterious im-
pact of systemic inflammatory events, such as infection, on isch-
emic brain injury, and highlight the importance of considering
the underlying immune status as a key modifier of stroke out-
come. We demonstrate that systemic inflammation aggravates
neurovascular proteolytic activity and exacerbates and alters the
kinetics of disruption to key components of the BBB after mild
focal cerebral ischemia. A rapid and transient claudin-5 disrup-
tion occurs after ischemia independently of systemic inflamma-
tion and is associated with phosphorylation of cerebrovascular
MLC. Systemic inflammation transforms this transient disrup-
tion to a sustained reduction in claudin-5.We identify infiltrating
neutrophil-derived MMP-9 as the perpetrator responsible for
this sustained BBB disruption because inhibition of MMP-9 re-
versed the sustained but not the hyperacute transient disruption.
These data imply that systemic inflammation alters the kinetics of
BBB tight-junction disruption via a peripherally derived MMP-
9-dependent phase of disruption that prevents the resolution of
the initial tight junction alterations induced independently of
MMP-9. The impact of these alterations on brain injury is under-
scored by our finding that inhibition of MMP-9 prevents the
exacerbation of brain damage, edema, and neurological deficit
caused by systemic inflammatory challenge.
Figure 6. Sustained aggravation of postischemic BBB disruption caused by systemic inflammation is dependent onMMP-9.A,
B, Systemic inflammation was induced by intraperitoneal IL-1 injection, and the effects of MMP-9 inhibition using the specific
inhibitor, SB-3CT, on the BBB tight junction protein, claudin-5 (A), and the cerebrovascular basal lamina protein, collagen-IV (B),
were assessed in cortical tissue ipsilateral to MCAo by immunoblot at indicated times after MCAo. A, MCAo induced a 75%
reduction in claudin-5 levels after 4 h reperfusion in vehicle (veh)- and IL-1-treated mice, and there was no effect of MMP-9
inhibition at this time point. Claudin-5 levels were restored to sham occlusion levels 8 and 24 h after MCAo, and there was no
significant effect of MMP-9 inhibition. Peripheral inflammatory challenge caused a sustained reduction in claudin-5 8 and 24 h
after MCAo, and these effects were significantly attenuated by inhibition ofMMP-9.B, Collagen-IV levels were similar after sham
occlusion andMCAo in vehicle-treatedmice at all time points examined. Peripheral inflammatory challenge induced a significant
reduction in collagen-IV 8 and24h afterMCAo, and these effectswere significantly attenuated by inhibition ofMMP-9. *p 0.05
versus vehicle, #p 0.05 versus IL-1, Kruskal–Wallis test followed by Dunn’s multiple-comparison test.
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There is growing evidence that inflammatory events out-
side the brain impinge on susceptibility, outcome, and prog-
nosis in a variety of neurological conditions, including cere-
bral ischemia (McColl et al., 2007b). Acute peripheral
inflammatory challenge worsens outcome after focal cerebral
ischemia (McColl et al., 2007a) and increases hippocampal
neuronal death after global cerebral ischemia (Spencer et al.,
2007). These effects are independent of core body and brain
temperature (Parry-Jones et al., 2008). Systemic inflammation
also sensitizes the brain to neonatal hypoxic and hemorrhagic
injury (Lehnardt et al., 2003; Xue and Del Bigio, 2005) and
exacerbates excitotoxic (Favrais et al., 2007) and traumatic
brain injury (Utagawa et al., 2008). The clinical relevance of
these findings is underlined by epidemiological and clinical
studies demonstrating that systemic infection is a risk factor
for stroke and that preceding infection is associated with less
favorable outcome (Emsley and Hopkins, 2008). Further-
more, systemic infection acquired after stroke is a common
complication and an important determinant of outcome in
animals and humans (Prass et al., 2003; Chamorro et al.,
2007). Collectively, these studies suggest that the systemic in-
flammatory profile in the peri-ischemic period is an important
variable that can modulate stroke
outcome. This concept parallels the
disease-modifying effects of systemic in-
flammation on chronic neurodegenera-
tion (Perry et al., 2007) and highlights an
important generic role for innate immu-
ne–brain interactions in acute and
chronic neurological dysfunction.
The mechanisms underlying the det-
rimental effects of systemic inflamma-
tion on ischemic brain injury are not
well understood. In the present study,
systemic inflammation altered the kinet-
ics of BBB tight-junction disruption by
converting a transient reduction in
claudin-5 to a sustained disruption that
did not resolve. Brain endothelial cells
are enriched in claudin-5 which is the
critical structural and functional ele-
ment for correct formation of tight junc-
tion strands and the limited paracellular
permeability of the BBB (Nitta et al.,
2003; Piontek et al., 2008). The present
data provide a potential explanation for
our previous results showing that sys-
temic inflammation induces a sustained
increase in BBB permeability and an ex-
acerbation of brain edema (McColl et al.,
2007a). In vehicle-challenged mice,
claudin-5 disruption and BBB perme-
ability were rapid and transient. A simi-
lar acute and resolving episode of BBB
permeability has been described in pre-
vious studies reporting a biphasic profile
of BBB opening after stroke in the ab-
sence of systemic inflammation (Belayev
et al., 1996; Rosenberg et al., 1998). In
view of these studies, our current data
suggest that this early BBB opening does
not resolve but is protracted when sys-
temic inflammation is coincident with
stroke. Although prolonged, the conversion from transient to
sustained BBB disruption occurs early and before the develop-
ment of increased brain damage caused by peripheral IL-1
challenge (McColl et al., 2007a) which supports a causative
role for these BBB alterations in the exacerbation of injury.
The consequences of unremitting loss of BBB integrity may be
manifold including excessive edema, raised intracranial pres-
sure and increased infiltration of hematogenous immune cells,
all of which are detrimental to stroke outcome. In support of
this, systemic inflammation significantly increased neutrophil
accumulation in the brain (McColl et al., 2007a).
An important finding in our current study is the identifi-
cation of MMP-9 as a key mediator underlying the sustained
disruption to cerebrovascular claudin-5 caused by systemic
inflammation. In contrast, MMP-9 was not responsible for the
rapid disruption to claudin-5 which preceded the MMP-9-
dependent phase in IL-1-challenged mice or the transient
disruption in vehicle-treated mice. Accordingly, our data im-
plicate MMP-9-independent (early) and MMP-9-dependent
(delayed) phases of tight-junction disruption and suggest that
MMP-9 perturbs claudin-5 expression in a temporally distinct
manner after stroke when there is coincident systemic inflam-
Figure 7. Inhibition of MMP-9 ameliorates the exacerbation of ischemic brain damage by systemic inflammation. Systemic
inflammation was induced by intraperitoneal IL-1 injection, and the effects of MMP-9 inhibition using the specific inhibitor,
SB-3CT, on the extent of ischemic brain damage, brain edema, and the severity of neurological deficit were determined 24 h after
MCAo. A–C, Systemic inflammation significantly exacerbated the volume of ischemic damage (A), the extent of brain edema (B),
and the neurological deficit (C). Inhibition of MMP-9 significantly attenuated the deleterious effects of systemic inflammation on
brain damage (A), edema (B), and neurological deficit (C). D, Representative cresyl violet-stained brain sections illustrate the
exacerbation of brain damage by systemic inflammation and the attenuation of this effect by SB-3CT. E, SB-3CT prevented the
hemorrhagic transformation (arrowheads) caused by systemic inflammation. F, G, Inhibition of MMP-9 also attenuated the
potentiationof neutrophil infiltration (F ) andgelatinolytic activity (G) causedbyperipheral inflammatory challenge.A,B,F: *p
0.05 versus vehicle (veh), #p 0.05 versus IL-1, one-way ANOVA followed by Student’s t test with Bonferroni correction; C:
*p 0.05 versus vehicle, #p 0.05 versus IL-1, generalized Fisher’s exact testwith Bonferroni correction. Scale bars, 100m.
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mation. Inhibition of MMP-9 restored collagen-IV levels to
baseline 4 h after MCAo confirming that the absence of an
effect on claudin-5 at this time point was not attributable to
lack of biological activity. MMP-9 has also been proposed
to disrupt other components of the endothelial tight-
junction-cytoskeletal framework, including claudin-3, ZO-1,
and occludin, and MMP-9 is associated with BBB breakdown
in a variety of neuroinflammatory conditions, including
ischemia-reperfusion, trauma, and infection (Rosenberg et al.,
1998; Wang et al., 2000; Asahi et al., 2001; Alvarez and Teale,
2007). Although we do not exclude that other mediators could
contribute to the sustained BBB disruption caused by systemic
inflammation, the present data do support an important role
for MMP-9.
The time-dependent effect of MMP-9 inhibition on BBB
disruption is consistent with the temporal profile of enhanced
neurovascular gelatinolytic activity associated with systemic
inflammation. A significant increase in gelatinolytic activity in
IL-1-challenged mice was not observed until 8 h after MCAo
and is explained by our data showing that infiltrating neutro-
phils are the primary source of MMP-9. We demonstrated
previously that systemic inflammation exacerbates neutrophil
infiltration after MCAo (McColl et al., 2007a) with similar
kinetics to the increase in gelatinolytic activity observed here.
These alterations precede the appearance of cortical damage in
IL-1-challenged mice (McColl et al., 2007a), further sup-
porting a causative role for enhanced MMP-9 activity in the
poorer outcome caused by systemic inflammation. Because
resident brain cells and infiltrating inflammatory cells can
both express MMP-9, our results indicate that systemic in-
flammation aggravates a peripheral inflammatory pathway
rather than stimulating MMP-9 expression directly in the
CNS. MMP-9 is stored as a zymogen in neutrophil granules
and on degranulation extracellular cleavage of the prodomain
exposes the zinc-binding catalytic site (Opdenakker et al.,
2001). Detection of cleaved MMP-9 only after systemic in-
flammatory challenge suggests that systemic inflammation
both elevates levels of MMP-9 and enhances the conversion to
the cleaved, active form. This could result from sensitization
of neutrophils to degranulation stimuli encountered at the
neurovascular compartment of the ischemic brain resulting in
enhanced release and activation. This suggests that peripheral
inflammatory events may alter the responsiveness of invading
immune cells to locally produced signals at the blood–brain
interface. In support of this, neutrophil and total leukocyte
counts and the extent of leukocyte-platelet adhesion and acti-
vation are elevated in ischemic stroke patients with preceding
infection (Emsley et al., 2003; Zeller et al., 2005).
The acute (4 h) disruption of claudin-5 in the present study
occurs independently of systemic inflammatory challenge and
MMP-9 activity. We did not detect an induction of MMP-2 or
MMP3 (stromelysin-1) (data not shown) both of which have
been implicated in claudin-5 degradation under neuroinflam-
matory conditions (Gurney et al., 2006; Yang et al., 2007). In
contrast, our results suggest that a protease-independent
mechanism may operate during this phase because we ob-
served an increase in phosphorylation of endothelial MLC 4 h
after MCAo that was independent of peripheral inflammatory
challenge. Further studies will investigate this in more detail.
MLC phosphorylation in endothelial cells induces transient
cytoskeletal reorganization, cell retraction, and conforma-
tional changes in tight junction proteins that can conceal im-
munoreactive epitopes and inhibition of MLC kinase prevents
hypoxia-induced opening of the BBB in vitro (Wysolmerski
and Lagunoff, 1990; Haorah et al., 2005; Kuhlmann et al.,
2007). This cascade could explain the severe but transient loss
of immunoreactive claudin-5 in vehicle-treated mice and the
hyper-acute MMP-9-independent phase of disruption in IL-
1-challenged mice. An important effect of systemic inflam-
mation is to limit resolution of this initial BBB disruption. The
BBB is therefore a point of convergence for systemically and
CNS-initiated inflammatory processes (Fig. 8).
The present findings may have clinical implications beyond
representing a mechanistic explanation for the poorer outcome
in stroke patients presenting with preceding infection. We ob-
served a higher incidence of HT in peripheral IL-1-challenged
mice that was prevented by inhibition ofMMP-9. Although spec-
ulative, this suggests stroke patients presenting with an elevated
systemic inflammatory profile (e.g., caused by preceding infec-
tion) may be at increased risk of MMP-9-mediated neurovascu-
lar proteolysis and HT, particularly when recombinant tissue
plasminogen activator, an inducer/activator of MMP-9 (Sumii
and Lo, 2002; Cuadrado et al., 2008), is administered for throm-
bolysis. Although there are currently no clinical data comparing
rates of HT in recombinant tissue plasminogen activator-treated
patients with and without infection, this may be an important
interaction to explore. In addition to infection, stroke patients
frequently present with comorbid diseases associated with
chronic elevations in systemic inflammation, such as atheroscle-
rosis anddiabetes. It will be important to investigate the impact of
such conditions on stroke outcome and to test the efficacy and
safety of putative stroke therapies in the context of acute and/or
chronic systemic inflammation in further preclinical studies.
In summary, our findings underline the critical involvement
of peripheral inflammatory pathways in stroke pathophysiology
and support the concept that priming of the innate immune sys-
tem has a deleterious impact on stroke outcome.
Figure 8. Temporal involvement of MMP-9 in BBB disruption underlying the exacerba-
tion of ischemic brain damage by systemic inflammation. Our data indicate two phases of
BBB disruption based on the involvement of MMP-9. The first phase is MMP-9-
independent and also occurs independently of systemic inflammation suggesting a local,
CNS-driven mechanism such as the cytokine/ROS-induced phosphorylation of endothelial
myosin light chain. This phase of BBB disruption is reversible when there is no additional
peripheral inflammatory stimulus. Systemic inflammation causes a secondary MMP-9-
dependent phase of disruption that is systemically driven (likely by neutrophils) and
compounds the initial disturbance and results in sustained and irreversible BBB dysfunc-
tion. The deleterious effects of systemic inflammation on ischemic brain damage highlight
the important position of the BBB as a point of convergence for CNS-driven and systemi-
cally driven inflammatory processes. veh, Vehicle.
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